1. Home
  2. BGLC vs NXL Comparison

BGLC vs NXL Comparison

Compare BGLC & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$2.32

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.36

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
NXL
Founded
2017
2010
Country
Malaysia
United States
Employees
N/A
7
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
8.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BGLC
NXL
Price
$2.32
$0.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.8K
114.0K
Earning Date
05-14-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
N/A
EPS
N/A
N/A
Revenue
$9,510,646.00
N/A
Revenue This Year
N/A
$120.99
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.36
52 Week High
$15.19
$2.31

Technical Indicators

Market Signals
Indicator
BGLC
NXL
Relative Strength Index (RSI) 43.18 34.70
Support Level $2.12 $0.37
Resistance Level $2.73 $0.46
Average True Range (ATR) 0.11 0.03
MACD 0.01 0.00
Stochastic Oscillator 34.31 7.60

Price Performance

Historical Comparison
BGLC
NXL

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: